Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 2/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 10/20 | 0.40 |
| ▸ | ILK | Q13418 | 2/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | NCS1 | P62166 | 1/20 | 0.39 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.38 |
| ▸ | AKR1A1 | P14550 | 3/20 | 0.37 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.37 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | SCN4A | P35499 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3673790 | 0.83 | DYRK1A (0.44) | DYRK1AAKR1B1ILKAKR1A1 | |
| SCHEMBL13508835 | 0.80 | DYRK1A (0.45) | DYRK1AAKR1B1MEN1KMT2A | |
| SCHEMBL3677914 | 0.76 | CHRM2 (0.44) | DYRK1AMEN1KMT2A | |
| SCHEMBL3677406 | 0.75 | GFER (0.45) | DYRK1AMEN1KMT2A | |
| SCHEMBL3680258 | 0.72 | DYRK1A (0.44) | DYRK1AMEN1KMT2A | |
| SCHEMBL22369860 | 0.69 | ILK (0.44) | DYRK1AAKR1B1ILKALOX5NCS1 | |
| SCHEMBL5847955 | 0.69 | CYP1A2 (0.49) | DYRK1AMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL22362685 | 0.68 | ILK (0.43) | DYRK1AAKR1B1ILKALOX5NCS1 | |
| SCHEMBL3673860 | 0.68 | ALDH1A1 (0.46) | MEN1KMT2A | |
| SCHEMBL3642935 | 0.68 | DYRK1A (0.58) | DYRK1AAKR1B1ILKALOX5NCS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1404659-B1 | 4-ARYL QUINOLS AND ANALOGS THEREOF AS THERAPEUTIC AGENTS | CANCER REC TECH LTD (GB) | 2010-02-10 | — | — | EP | disclosed |
| EP-1404659-B1 | 4-ARYL QUINOLS AND ANALOGS THEREOF AS THERAPEUTIC AGENTS | CANCER REC TECH LTD (GB) | 2010-02-10 | — | — | EP | disclosed |
| US-20060287396-A1 | 4-aryl quinols and analogs thereof as therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2006-12-21 | — | — | US | disclosed |
| US-7144893-B2 | 4-aryl quinols and analogs thereof as therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2006-12-05 | — | — | US | disclosed |
| US-20040220236-A1 | 4-Aryl quinols and analogs thereof as therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2004-11-04 | — | — | US | disclosed |
| EP-1404659-A1 | 4-ARYL QUINOLS AND ANALOGS THEREOF AS THERAPEUTIC AGENTS | Cancer Research Technology Limited (GB) | 2004-04-07 | — | — | EP | disclosed |
| WO-2003004479-A1 | 4-ARYL QUINOLS AND ANALOGS THEREOF AS THERAPEUTIC AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287396-A1 | 4-aryl quinols and analogs thereof as therapeutic agents | TXNRD3, TXNRD1, TXN | DYRK1A 802/4885AKR1B1 19/4885ILK 4399/4885 |
| US-20040220236-A1 | 4-Aryl quinols and analogs thereof as therapeutic agents | TXNRD1, TXNRD3, TXNRD2 | DYRK1A 1691/4885AKR1B1 23/4885ILK 4557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.